The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 20, 2020

Filed:

Nov. 28, 2019
Applicant:

Jiangnan University, Wuxi, CN;

Inventors:

Hua Kuang, Wuxi, CN;

Lingling Guo, Wuxi, CN;

Chuanlai Xu, Wuxi, CN;

Liguang Xu, Wuxi, CN;

Wei Ma, Wuxi, CN;

Liqiang Liu, Wuxi, CN;

Shanshan Song, Wuxi, CN;

Xiaoling Wu, Wuxi, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/44 (2006.01); G01N 33/94 (2006.01);
U.S. Cl.
CPC ...
C07K 16/44 (2013.01); G01N 33/9446 (2013.01); C07K 2317/92 (2013.01); G01N 2430/00 (2013.01);
Abstract

The present disclosure discloses a lincosamides universal monoclonal antibody hybridoma cell strain and application thereof, and belongs to the technical field of food safety immunological detection. According to the present disclosure, a clindamycin chlorine-substituted derivative is used as a hapten, the hapten is coupled with bovine serum albumin (BSA) by an activated ester method to obtain an immunizing antigen, and after being uniformly mixed with a Freund's adjuvant, the immunizing antigen is subcutaneously injected to immunize BALB/c mice; clindamycin is coupled with ovalbumin (OVA) by a carbonyl diimidazole (CDI) method to be used as a coating antigen used for detecting mouse serums and a cell supernatant. The spleen cells of the immunized mice are fused with mouse myeloma cells by a PEG method, and screened by indirect ELISA and indirect competitive ELISA and subcloned three times to obtain a population-selective hybridoma cell strain. The cell strain provided by the present disclosure has relatively good inhibition on clindamycin, lincomycin and pirlimycin, and can meet the demand for lincosamides multi-residue immunoassay products on the market.


Find Patent Forward Citations

Loading…